|Recombinant Human CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Val241.
|CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.
|CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341
|The protein has a predicted MW of 48.5 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.
|Immobilized Human CLEC9A, hFc Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-CLEC9A Antibody, hFc Tag with the EC50 of 5.9ng/ml determined by ELISA. See testing image for detail.
|> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
|Less than 1EU per ug by the LAL method.
|Shipped at ambient temperature.
|Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
|Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
|Stability And Storage
|Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.